Kyntra Bio, Inc. is a biopharmaceutical company, which engages in the discovery, development, and commercialization of novel therapeutics.
$3.20-6.98%
报价 2026-11-16
市值
$13M
EV
$-19.3M
PE (TTM)
0.2x
预期 PE (FY2026)
–
52 周区间距高点 -68.1%
$3.20$10.04
筛选结果
pipeline · 2026-11-16Filter✗ 高增长✗ Cheap✗ GARP
market cap below $300M floor
研究结论
还没有研究记录。先生成 L2 基本面报告(约 1–3 分钟),结论会显示在这里。
去生成基本面报告 →历史股价
加载中…
事件
0 条 · 随区间与图例筛选该区间内无事件。
同行对比
FMP 同行列表 · 2026-05-16| 公司 | 市值 | 今日 | 预期营收增速 | 毛利率 | PE | EV/EBITDA | P/FCF | 池 |
|---|---|---|---|---|---|---|---|---|
| KYNBKyntra Bio, Inc. | $13M | -7.0% | +16.2% | 75.8% | 0.2x | – | – | |
| XFORX4 Pharmaceuticals, Inc. | $289M | -9.3% | -49.4% | 81.2% | – | – | – | |
| OKUROnKure Therapeutics, Inc. | $111.4M | +4.6% | -28.6% | 0% | – | – | – | |
| XLOXilio Therapeutics, Inc. | $54.4M | -4.6% | -12.2% | 0% | – | – | – | |
| PDSBPDS Biotechnology Corporation | $51.6M | +5.9% | +2700.0% | 0% | – | – | – | |
| ATNMActinium Pharmaceuticals, Inc. | $46.8M | -9.1% | +12800.0% | 101.1% | 4.0x | 0.8x | – | |
| CELUCelularity Inc. | $20.1M | -1.7% | +76.0% | 19.2% | – | – | – | |
| ALGSAligos Therapeutics, Inc. | $10.4M | -21.0% | +528.0% | 99.2% | – | – | – | |
| TPSTTempest Therapeutics, Inc. | $6.8M | -10.5% | +17800.0% | 0% | – | – | – | |
| 同行中位数 | – | – | +302.0% | 9.6% | 4.0x | 0.8x | – |
研究全文
L2 基本面 memo
尚无基本面 memo
点击「生成基本面报告」——基于最新 filings、电话会纪要与分析师共识生成 L2 memo。
财务报表
暂无季度数据(首次研究运行后填充)。